Request Demo

Last update 25 Apr 2026

Triapine

Last update 25 Apr 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Triapine, 3-AP, NSC#663249

+ [5]

Target

RNRs

Action

inhibitors

Mechanism

RNR inhibitors(Ribonucleotide reductase inhibitors)

Therapeutic Areas

NeoplasmsUrogenital DiseasesOther Diseases+ [2]

Active Indication

Adenosquamous CarcinomaCervical Squamous Cell CarcinomaSquamous Cell Carcinoma+ [9]

Inactive Indication

Acinar Cell CarcinomaAcute Promyelocytic LeukemiaAdenocarcinoma of Esophagus+ [61]

Originator Organization

Nanotherapeutics, Inc.

Active Organization

National Cancer Institute

Nanopharmaceutics, Inc.

Nanotherapeutics, Inc.

Inactive Organization

Vion Pharmaceuticals, Inc.

License Organization

Resilience Government Services, Inc.

Trethera Corp.

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC7H9N5S

InChIKeyXMYKNCNAZKMVQN-UHFFFAOYSA-N

CAS Registry143621-35-6

Clinical Trials associated with Triapine

NCT06860594

/ SuspendedPhase 1IIT

A Phase I Trial Combining Triapine With Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving triapine in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.

Start Date30 Jul 2025

Sponsor / Collaborator

National Cancer Institute

NCT06410248

/ Active, not recruitingPhase 1IIT

A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.

Start Date23 Jul 2024

Sponsor / Collaborator

Northwestern University

[+2]

NCT05724108

/ Active, not recruitingPhase 2IIT

A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors

This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.

Start Date30 Aug 2023

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Triapine

100 Translational Medicine associated with Triapine

100 Patents (Medical) associated with Triapine

370

Literatures (Medical) associated with Triapine

01 Dec 2025·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)

Article

Author: Randall, Leslie M ; Vargo, John ; Kohn, Elise C ; Orr, Brian ; Ivy, S Percy ; Courtney-Brooks, Madeleine ; Mahdi, Haider ; Lin, Yan ; Behr, Sarah ; Fabian, Denise ; Beriwal, Sushil ; Gallion, Holly ; Richardson, Debra L ; Chu, Edward ; Beumer, Jan H ; Kunos, Charles ; Huang, Marilyn ; Taylor, Sarah E ; Ueland, Frederick ; Girda, Eugenia ; Olawaiye, Alexander B ; Sullivan, Stephanie A ; Chauhan, Aman ; Cooper, Kristine L ; Christner, Susan M

BACKGROUND:

The addition of IV triapine to chemoradiation appeared active in phase I and II studies but drug delivery is cumbersome. We examined PO triapine with cisplatin chemoradiation.

METHODS:

We implemented a 3 + 3 design for PO triapine dose escalation with expansion, starting at 100 mg, five days a week for five weeks while receiving radiation with weekly IV cisplatin for locally advanced cervical or vaginal cancer. Maximum tolerated dose (MTD), dose limiting toxicity (DLT), adverse events, pharmacokinetics (PK), pharmacodynamics (PD), and metabolic complete response (mCR) were assessed.

RESULTS:

19/21 patients were DLT evaluable. DLTs included grade 4 neutropenia (n = 2), leukopenia (n = 2), lymphopenia (n = 2), and hypokalemia (n = 1). Grade 3 toxicities at least possibly related were as expected for cisplatin chemoradiation: lymphopenia (n = 12), anemia (n = 10), neutropenia (n = 4), leukopenia (n = 8), decreased platelets (n = 2), hypertension (n = 1), and hyponatremia (n = 1). MTD and RP2D were established at 100 mg. 8/13 evaluable patients had a mCR. Triapine had a bioavailability of 59%. Methemoglobin levels correlated with triapine exposure. Smoking almost doubled CYP1A2 mediated triapine clearance.

CONCLUSIONS:

Oral triapine is safe when given with cisplatin chemoradiation, convenient, bioavailable. Exposure is negatively impacted by smoking, and methemoglobin is a biomarker of exposure.

CLINICAL TRIAL REGISTRATION:

NCT02595879.

01 Aug 2025·JOURNAL OF MOLECULAR HISTOLOGY

Does Moringa oleifera leaf extract protect the brain against 3-acetylpyridine-induced cerebellar ataxia in rat?

Review

Author: Sedeak, Ahmed Yahia ; Hassan, Doaa Mohamad ; Sabra, Nourhan Tharwat ; Farghaly, Maha Eid

There is no treatment for some neurological conditions, like cerebellar ataxia (CA). Moringa Oleifera (MO) has been revealed to have neuroprotective properties, but little is known about how it could protect against CA. In this study, we studied the neuroprotective effects of MO in an animal model of CA induced by 3-acetylpyridine (3-AP), which showed deficits in balance and motor coordination. Although cerebellar neuroinflammatory responses are evident in CA, it is yet unclear how neuroinflammation might influence CA. Here, we investigate whether MO, which has anti-inflammatory, antioxidant, and neuroprotective qualities, can help with cerebellar neurodegeneration and locomotor activity deficits. We divided 24 adult male rats into four equal groups. The control group received saline orally, the MO group received MO extract orally, the 3-AP group was injected with 3-AP, and the 3-AP + MO combined group received both 3-AP and MO for four weeks. The animals underwent a motor coordination test on the experiment's first and last days. At the end of the experiment, the animals were euthanized, the cerebellums were dissected, and they were then subjected to standard biochemical, histological, and immunohistochemical studies. The combined group showed remarkable improvement in the CA. The cerebellar neurodegeneration and declination of locomotor activity had improved. Our findings imply that MO may protect against the CA degenerative condition and improve cerebellar function.

01 Apr 2025·GYNECOLOGIC ONCOLOGY

Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial

Article

Author: Feddock, Jonathan M ; Deng, Wei ; Monk, Bradley J ; Chino, Junzo P ; Mell, Loren K ; Amarnath, Sudha R ; Arend, Rebecca C ; Walker, Joan L ; Santos-Reyes, Luis Javier ; Kunos, Charles M ; Ghamande, Sharad A ; Albuquerque, Kevin ; Lea, Jayanthi S ; Aghajanian, Carol ; Chon, Hye Sook ; Jegadeesh, Naresh ; DiSilvestro, Paul ; Richardson, Debra L ; Mayadev, Jyoti ; Donnelly, Eric ; Holman, Laura L ; MacKay, Helen ; Gao, Lei ; Quick, Allison M ; Lowenstein, Jessica ; Leath, Charles A

BACKGROUND:

Cisplatin-based chemoradiation (CRT) plus brachytherapy for locally advanced cervical cancer (LACC) is standard. Intrinsic overexpression of ribonucleotide reductase (RNR) may enhance DNA damage repair from CRT. We report on outcomes of adding RNR inhibitor, triapine (T), to CRT.

METHODS:

NRG-GY006 is an open-label randomized phase III trial. FIGO 2009 LACC (stages IB2, II, IIIB or IVA) without para-aortic nodal involvement or stages II-IV vaginal cancer were eligible. Random assignment to CRT or in combination with thrice-weekly T (CRT + T) occurred. Radiation consisted of either 3D conformal (3DCRT) or image-guided intensity modulated RT (IG-IMRT) followed by intracavitary brachytherapy. Primary endpoint was overall survival (OS). Progression-free survival (PFS) was secondary. Exploratory endpoints included complete metabolic response rate on post treatment PET/CT imaging and comparative toxicity and outcomes for 3DCRT vs. IG-IMRT.

FINDINGS:

Four-hundred-fifty patients were randomized including 448 eligible (224 in CRT and 224 in CRT + T). Median age was 47 (range 23-85). The majority had cervical cancer (93.3 %) with squamous histology (82 %). 52 % had FIGO stage II disease. Racial/ethnic distribution included non-Hispanic white (53.8 %), black (15.2 %) and Hispanic/Latina (22.5 %). At randomization, IG-IMRT was planned in 74.3 % and HDR brachytherapy in 98.2 %. No differences in Grade 3-5 toxicities were observed: CRT: 52 % and CRT + T: 49 %, with two G5 toxicities (cardiac arrest and acidosis) in the CRT + T arm. The median patient follow-up was 28 months (IQR 15-45). HR for death was 1.018 (95 % CI 0.634-1.635) while HR for progression was 1.021 (95 % CI 0.694-1.501).

INTERPRETATION:

Triapine added to CRT did not improve OS.

News (Medical) associated with Triapine

10 Sep 2025

·www.einpresswire.com

Nanopharmaceutics Announces Presentation of National Cancer Institute sponsored Phase I Study with Triapine at ESMO 2025

Phase I Study with Triapine + Lutetium Lu 177 Dotatate in patients with progressive well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) TRON Group Inc. (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, September 10, 2025 / EINPresswire.com / -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced a presentation of the National Cancer Institute (NCI) sponsored Phase I Study 10388 (NCT04234568) “Testing the Addition of an Anti-cancer Drug, Triapine , to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors” in an oral presentation at the European Society for Medical Oncology (ESMO) Congress, held from October 17-21, 2025 in Berlin, Germany. The data will be presented on the October 20th Mini oral session: NETs and endocrine tumours “1709MO - Multi-center NCI-sponsored phase 1 study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)” at the 2025 European Society of Medical Oncology (ESMO) Congress by Aman Chauhan, MD, Associate Professor of Medical Oncology, Leader of Neuroendocrine Tumor Program and Co-Director of Theranostics Program, University of Miami Sylvester Comprehensive Cancer Center. This study was sponsored by the National Cancer Institute (NCI), part of National Institutes of Health, and conducted by the NCI funded Experimental Therapeutics Clinical Trials Network (ECTCN). The end of patient recruitment was recently announced for a NCI-sponsored randomized phase 2 trial 10558 (NCT05724108) “Testing the Effectiveness of an Anti-cancer Drug, Triapine ® , When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors” currently underway at 14 sites across the United States. This 94 patient phase II trial recently passed the pre-planned interim safety review and interim futility assessment and is awaiting primary endpoint maturity. Both studies are being performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics and conducted by ECTCN. About Triapine ® Triapine ® is s synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine ® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Nanopharmaceutics is a subsidiary of TRON Group Inc. (OTC:TGRP). James D Talton Nanopharmaceutics, Inc. +1 386-401-6304 info@nanopharmaceutics.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2Phase 1Clinical Result

18 Jul 2025

·www.einpresswire.com

Nanopharmaceutics Announces End of Patient Recruitment for NCI Phase II Study with Triapine for Neuroendocrine Tumors

Nanopharmaceutics Inc. Announces End of Patient Recruitment of NCI Phase II Clinical Study with Lutetium Lu 177 Dotatate +/- Triapine for Neuroendocrine Tumors TRON Group Inc (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, July 18, 2025 / EINPresswire.com / -- ALACHUA, Fla., July 18, 2025 -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 94 patient Phase 2 clinical study “A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors”. The study (NCI protocol 10558, ClinicalTrials.gov Identifier: NCT05724108) is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, conducted by NCI funded Experimental Therapeutics Clinical Trials Network (ETCTN) with the Ohio State University Comprehensive Cancer Center as the lead institution. The randomized phase 2 trial is evaluating (PRIMARY OBJECTIVE) the overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of combination Triapine ® + lutetium Lu 177 dotatate (treatment arm 1) versus standard of care lutetium Lu 177 dotatate alone (treatment arm 2) and (SECONDARY OBJECTIVE) to evaluate progression-free survival (PFS) between the two treatment arms (combination arm 1 versus standard of care arm 2). This phase II trial compares the effect of adding Triapine ® to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine ® may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. This study tests whether adding Triapine ® improves shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone. 94 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. The phase II trial passed the pre-planned interim safety review and interim futility assessment and is awaiting primary endpoint maturity. About Triapine ® Triapine ® is s synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine ® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Nanopharmaceutics is a subsidiary of TRON Group Inc. (OTC:TGRP). James D. Talton, Ph.D. Nanopharmaceutics, Inc. +1 386-401-6304 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2Clinical Result

14 May 2024

·www.prnewswire.com

Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Patients with Recurrent Glioblastoma

ALACHUA, Fla. and CHICAGO, May 14, 2024 /PRNewswire/ -- Nanopharmaceutics, Inc. (OTC:TGRP), a clinical-stage pharmaceutical development company, announced the initiation of a Phase I clinical study with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University "A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma" (ClinicalTrials.gov Identifier: NCT06410248). The primary objective of this phase 1 study will be to determine the recommended phase 2 dose (RP2D) for Triapine® in combination with temozolomide (TMZ). Secondary objectives include evaluation of the safety profile of Triapine® in combination with temozolomide (TMZ), progression-free survival (PFS), overall survival (OS), overall response rate (ORR) per RANO criteria, and quality of life per FACT-Br. The study will recruit 40-45 patients with an established diagnosis of recurrent glioblastoma, and there will be an exploratory arm to investigate drug delivery into brain tumor tissue and target engagement in a cohort who are surgical candidates for re-resection of recurrent glioblastoma. Funding for the study is provided by BrainUp. Oral Triapine® has been shown to be safe, tolerable, and convenient in multiple clinical studies. Ribonucleotide Reductase (RNR) Regulatory Subunit 2 (RRM2) targeting with Triapine® may overcome chemoresistance and improve the clinical efficacy of TMZ therapy. Preliminary research from Dr. Atique Ahmed's lab at Northwestern University has uncovered a critical factor that helps glioblastoma, an aggressive brain cancer, resist chemotherapy treatment. About the Robert H. Lurie Comprehensive Cancer Center of Northwestern University The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is a National Cancer Institute-designated Comprehensive Cancer Center located on Northwestern Memorial Hospital's downtown medical campus in the Streeterville neighborhood of Chicago, Illinois, United States. About BrainUp BrainUp is a nonprofit founded by Dan & Meg Kresach of Frankfort, Illinois. They founded BrainUp after their only child Olivia, was diagnosed 10 years ago with a Glioblastoma at the age of 22 years old. She died on April 19, 2014. The Kresachs formed BrainUp to fund brain cancer research. They have an annual run/walk to raise money for brain cancer research. They have funded over 1.2 million dollars supporting brain cancer research and trials at Chicago healthcare institutions. BrainUp is the financial supporter of Karan Dixit, M.D. (PI) and Atique Ahmed, Ph.D of Northwestern University Chicago, Illinois. To learn more about BrainUp, visit brainup.ngo About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver BCS category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. (OTC: TGRP) James D. Talton, Ph.D. President and Chief Executive Officer 386-401-6304 SOURCE Nanopharmaceutics, Inc.

Phase 1Oligonucleotide

100 Deals associated with Triapine

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11940

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenosquamous Carcinoma	Phase 3	United States	National Cancer Institute	10 May 2016
Adenosquamous Carcinoma	Phase 3	Canada	National Cancer Institute	10 May 2016
Cervical Squamous Cell Carcinoma	Phase 3	United States	National Cancer Institute	10 May 2016
Cervical Squamous Cell Carcinoma	Phase 3	Canada	National Cancer Institute	10 May 2016
Squamous Cell Carcinoma	Phase 3	United States	National Cancer Institute	10 May 2016
Squamous Cell Carcinoma	Phase 3	Canada	National Cancer Institute	10 May 2016
Uterine Cervix Adenocarcinoma	Phase 3	United States	National Cancer Institute	10 May 2016
Uterine Cervix Adenocarcinoma	Phase 3	Canada	National Cancer Institute	10 May 2016
Vagina Carcinoma	Phase 3	United States	National Cancer Institute	10 May 2016
Vagina Carcinoma	Phase 3	Canada	National Cancer Institute	10 May 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02595879 (ETCTN 9892, Pubmed \| Cancer Chemother Pharmacol)	Phase 1/2	Vaginal Neoplasms \| Locally Advanced Cervical Carcinoma methemoglobin levels \| smoking \| CYP1A2	21	Oral Triapine 100 mg	jaznsdkvhr(bxepktejfh) = almost doubled CYP1A2 mediated triapine clearance qxowekewnd (npsxxqlfze ) View more	Positive	01 Dec 2025
NCT04234568 (###DELETE, CTgov)	Phase 1	Somatostatin Receptor-Positive Neuroendocrine Tumor \| Gastro-Enteropancreatic Neuroendocrine Tumor	31	Triapine+lutetium Lu 177 dotatate (Escalation Phase)	goamxqpjem = wjxyemdyeh fxlwzajqlk (cqpugmfecf, skuvekmymb - xzrjuoybeu)	-	03 Nov 2025
				Triapine+lutetium Lu 177 dotatate (Expansion Phase)	goamxqpjem = ovwetktysy fxlwzajqlk (cqpugmfecf, sgdoheloiq - cyjmvmhmye)
NCT02595879 (ETCTN 9892, CTgov)	Phase 1	Adenosquamous Carcinoma \| Vagina Carcinoma \| Locally Advanced Cervical Carcinoma ... View more	21	triapine (All Participants)	yzbghmwuxp = iiwzwnpafr gbtbnehkqe (jxnlbwmwna, iepvbxgqtn - eghbtijqtw)	-	16 Oct 2024
				Triapine (Triapine (100mg) + Chemoradiation))	mmdadiwtct = hkxysrpgwb jebnjplbpn (uqkleibnhm, uigqwfozrk - kuovwuntwr) View more
NCT02466971 (NRG-GY006, CTgov)	Phase 3	Adenosquamous Carcinoma \| Vagina Carcinoma \| Cervical Squamous Cell Carcinoma ... View more	450	Intensity-Modulated Radiation Therapy+cisplatin (Arm I (Cisplatin, IMRT or RT, Brachytherapy))	hcezuckpvm = tnkqtayqav vxboctbdno (fvnxdwgmzd, bowrdglfqi - vdrgzrdlck) View more	-	05 Jan 2024
				Intensity-Modulated Radiation Therapy+Triapine+cisplatin (Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine))	hcezuckpvm = wumxeswwnt vxboctbdno (fvnxdwgmzd, vojbdkxvrr - mwtfnajqay) View more
NCT02466971 (NRG-GY006, ASCO2023)	Phase 3	Vaginal Neoplasms \| Locally Advanced Cervical Carcinoma	448	Cisplatin + RT	qugzddajgw(rcrlravhgs): HR = 1.018 (95% CI, 0.634 - 1.635) View more	Negative	31 May 2023
				Cisplatin + RT + Triapine
NCT04234568 (AACR2023) Manual	Phase 1	Gastro-Enteropancreatic Neuroendocrine Tumor SSTR Expression	31	triapine+Lutetium Dotatate LU-177	zcsemiygkc(isjrrobggt) = One DLT in dose level 1, seven DLTs in dose level 2, and one grade 5 DLT in dose level 3 were observed. jcewlfscwz (shfradubpm ) View more	Positive	14 Apr 2023
NCT04234568 (ASCO_GI2023) Manual	Phase 1	SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor SSTR1 Expression	31	triapine+lutetium Lu-177 dotatate	dpnazyszuu(vwgkqolpnv) = uckdiqqndg oweaufhohp (ivilsddwnm ) View more	Positive	24 Jan 2023
NCT04234568 (ASCO2020)	Phase 1	Neuroendocrine Tumors First line	29	Triapine and Lutetium Lu 177 Dotatate	zxlseamdbq(fqxuybqjut) = fzspgazzzu mipweassqt (vmukbuyiog )	-	25 May 2020
NCT02466971 (Pubmed \| Front Oncol) Manual	Phase 2	Vaginal Neoplasms \| Uterine Cervical Diseases	26	cisplatin+Radiotherapy+triapine	jxafkflifj(hyghvqtegz) = fbnbevzysk dkzxbisefh (njkmgbuhez ) View more	Positive	15 Oct 2019
				cisplatin+Radiotherapy	jxafkflifj(hyghvqtegz) = kzepuxzefr dkzxbisefh (njkmgbuhez ) View more
NCT00016874 (Pubmed \| Front Oncol) Manual	Phase 1	Solid tumor	13	cisplatin+paclitaxel+triapine	fpodxqntei(hkishikzrp) = triapine (80 mg/m2), cisplatin (50 mg/m2), paclitaxel (80 mg/m2) vjznfylmpl (nebgfoafrj ) View more	Positive	04 Apr 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis